Floatz logo

Neflamapimod

Mild Cognitive Impairment

EIP Pharma IncSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

150 Active assets in the Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

Neflamapimod is also rated in:

Lewy body dementiaDormant
BB
Indicative ·
66 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
57 / 100
View asset →
progressive non-fluent aphasiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →